PHARMACY

Takeda, Ultragenyx partner to develop rare genetic disease treatments

BY David Salazar
NOVATO, Calif. and OSAKA, Japan — Takeda on Tuesday announced a new partnership with Ultragenyx Pharmaceutical to develop and commercialize therapies for rare genetic diseases. 
 
Under the partnership, Ultragenyx will initially receive an exclusive license for one of Takeda’s preclinical product candidates in a pre-determined field of use, along with the option to co-develop and co-commercialize the candidate in other therapeutic areas. Additionally, the two companies have established a five-year research collaboration that will give Ultragenyx the option to license as many as five Takeda product candidates for rare diseases once the companies agree on and conduct initial validation activities under a joint research committee. 
 
“This broad collaboration provides Ultragenyx with a product opportunity that is approaching clinical-stage development as well as a potential continued source of new product candidates that will help us achieve our goal of bringing a new therapy into the clinic every one to two years,” Ultragenyx CEO Emil Kakkis said. “Takeda has an impressive early pipeline of therapies with potential across a number of rare genetic diseases, and we are pleased that Takeda has chosen to partner with us to bring these therapies to patients with rare diseases that have few or no treatment options.”
 
Takeda will have the exclusive option to commercialize any licensed products that are the result of the collaboration in Asia and it will have the option to exclusively license one Ultragenyx pipeline products in Japan. Takeda will invest up to $65 million in Ultragenyx in two tranches, the first of which will be a $25 million stock purchase and $15 million cash premium at closing. Ultragenyx’s option will see a second equity purchase of 25 million with no additional premium. No additional financial details were disclosed. 
 
“Ultragenyx is a rapidly emerging rare disease company, led by a highly experienced and successful management team,” Takeda chief medical and scientific officer Dr. Andrew Plump said. “This partnership provides Takeda access to Ultragenyx's strong patient-centric development and regulatory capabilities in the rare disease space, and could create significant value for both companies by delivering important new therapies to patients.”
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

DSNTV: Innovation’s Doyle Jensen discusses central fill and the future of pharmacy automation

BY David Salazar

Drug Store News recently caught up with Doyle Jensen, EVP global business development at pharmacy automation company Innovation to talk about the company’s offerings for pharmacies looking to move toward a high-volume central-fill solution.

Jensen also discusses how the company works as a technology partner to move pharmacy automation forward, how it works with retailers to address challenges and the promising future of automation that was on display at Innovation’s and Binghamton University’s Watson Institute for Systems Excellence’s recent symposium.

To read more about the Innovation-BU Wise symposium, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

McKesson unveils 5 ways value-based reimbursement is trending

BY Michael Johnsen
NEWTON, Mass. – Executives from McKesson Health Solutions and researcher ORC International will unveil the results of a new national research study on value-based reimbursement trends, commissioned by McKesson, at an exclusive session during AHIP’s Institute 2016, the companies announce Tuesday. 
 
The research will reveal how much progress healthcare has made on the journey to full value-based payment, where the industry sees itself in two and five years, which payment models are growing fastest, where payers and providers are succeeding, what the challenges are and predictive trends. 
 
“Healthcare reimbursement is evolving fast and that’s increasing the complexity of reimbursement,” stated Carolyn Wukitch, SVP and general manager, Network and Financial Management, McKesson Health Solutions. “This is a rare chance to learn how both payers and providers are reacting, what strategies they’re using and plan to use, what’s working, where the gaps are, and how they can win in an increasingly value-based and consumer-driven healthcare world.”
 
In addition to Wukitch, the session, “Market Update: New Research Insights on Reimbursement Models,” will be presented by Andrei Gonzales, director of VBR initiatives and Dana Benini, VP ORC International. 
 
It will be held at AHIP’s Institute 2016 at the Wynn/Encore in Las Vegas on June 16. 
 
The AHIP Institute 2016 event brings healthcare professionals together to tackle challenges, uncover opportunities, and work together to advance healthcare. At the show, McKesson will feature its comprehensive suite of reimbursement solutions that help payers and providers eliminate waste, ensure accurate and timely payment, promote quality care and support wise consumer decisions.
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?